Short Notes in Cytology

1. Liquid-Based Cytology (LBC)

• ThinPrep (Hologic): Cells are collected into a vial of PreservCyt solution. A filter membrane rotates through the sample, and cells are transferred to a slide.
• SurePath (BD Diagnostics): Cells are dispersed in a ethanol-based preservative, and a density gradient centrifugation produces a cell pellet that is then transferred to a slide.

• Elimination of drying artifact and obscuring blood/mucus
• Uniform thin-layer cell distribution (monolayer)
• Residual material in the vial can be used for ancillary tests (HPV DNA testing, immunocytochemistry, molecular studies)
• Improved detection of HSIL/LSIL lesions
• Automated screening compatible (imager systems)
• Better cell preservation

• High cost of equipment and consumables
• Loss of 3D architectural patterns (e.g., syncytial aggregates less evident)
• Requires dedicated training
• Endocervical cells may be distributed differently

2. Role of FNAC in Small Blue Round Cell Tumors (SBRCTs)

• Ewing's sarcoma / PNET
• Neuroblastoma
• Rhabdomyosarcoma (embryonal / alveolar)
• Non-Hodgkin's lymphoma (especially Burkitt's, lymphoblastic)
• Wilms' tumor (nephroblastoma)
• Medulloblastoma
• Small cell carcinoma (lung)
• Desmoplastic small round cell tumor (DSRCT)
• Merkel cell carcinoma

• Immunocytochemistry (ICC): CD99 (Ewing's), CD45 (lymphoma), desmin/myogenin (RMS), synaptophysin/chromogranin (neuroblastoma), WT1 (Wilms')
• Cytogenetics/FISH: t(11;22) Ewing's; MYCN amplification (neuroblastoma); PAX3-FOXO1 (alveolar RMS)
• RT-PCR / molecular: Fusion gene detection from FNAC material

3. FNAC of Soft Tissue Tumors (STTs)

• Sensitivity ~70-80% for malignancy; grading accuracy limited
• Two-step approach: FNAC for malignant vs. benign -> Core needle biopsy for definitive subtyping and grading
• Ancillary: IHC panel, cytogenetics (SYT-SSX for synovial sarcoma), MDM2 amplification (WD liposarcoma)

4. Bronchoalveolar Lavage (BAL) Cytology

• Alveolar macrophages: 80-90%
• Lymphocytes: 5-15%
• Neutrophils: <3%
• Eosinophils: <1%
• Mast cells: <0.5%

5. Intraoperative Cytology (IOC)

1. Squash/Crush preparation: Tissue compressed between two slides - rapid, good for soft tissue (brain tumors)
2. Imprint/Touch preparation: Cut surface of tissue touched to slide
3. Scrape preparation: Cut surface scraped with a scalpel
4. Needle aspiration during surgery
5. Smear (for fluid specimens)

• CNS tumors: Distinguish glioma, meningioma, metastasis, medulloblastoma
• Lymph nodes: Frozen section equivalent for nodal status (sentinel node)
• Thyroid: Adequacy of resection; assess recurrence
• Parathyroid: Confirm parathyroid tissue during neck exploration
• Bone/soft tissue: Confirm malignancy before wide resection
• Liver/pancreas: Confirm metastasis or primary lesion
• Breast: Confirm adequacy of excision

• Faster than frozen section (15-20 min vs. 30 min)
• No freezing artifact
• Excellent cytomorphological detail
• Small tissue requirement

• Small tissue fragments may not be representative
• Cannot assess architecture
• Grade and subtype may not be determined with certainty
• Requires experienced cytopathologist
• Some tumors (e.g., fibrous, calcified) do not yield adequate smears

6. Bethesda System for Cervical Cytology (TBS)

Specimen Adequacy

• Satisfactory for evaluation (with or without endocervical/transformation zone component)
• Unsatisfactory for evaluation (specify reason)

General Categorization

• Negative for Intraepithelial Lesion or Malignancy (NILM)
• Epithelial Cell Abnormality
• Other (e.g., endometrial cells in women ≥45 years)

NILM includes:

• Organisms: Trichomonas, Candida, shift in flora (BV), Actinomyces, Herpes, CMV
• Reactive changes, atrophy, radiation changes, IUD-related changes

Epithelial Cell Abnormalities:

Management (2019 ASCCP guidelines):

• ASC-US: reflex HPV testing; if HPV+, colposcopy
• LSIL: colposcopy
• ASC-H/HSIL: immediate colposcopy
• AGC: colposcopy + endometrial sampling

7. CSF Cytology

• Lumbar puncture; specimen must be processed within 1 hour (cells lyse rapidly)
• Cytocentrifugation (cytospin) is mandatory for optimal yield
• Papanicolaou and MGG stains; cell count and differential performed

• <5 WBCs/mm³ (adults); predominantly lymphocytes
• No RBCs (except traumatic tap)
• No malignant cells

• Single lumbar puncture: ~45-50%
• Three lumbar punctures: ~80-90%
• Large volume (>10 mL) improves yield

8. Exfoliative Cytology

1. Spontaneous exfoliation: Cells shed naturally into body cavities/fluids
   • Urine, sputum, CSF, pleural/peritoneal/pericardial effusions, gastric washings
2. Induced/Mechanical exfoliation: Cells obtained by scraping/brushing
   • Cervical/vaginal scrapes (Pap smear), bronchial brushings, buccal smears, esophageal brushings

9. Sputum Cytology and Its Utility in Diagnosis

• Fresh sputum: Collected immediately after a deep cough on 3 consecutive mornings (first morning, post-cough specimen is best)
• Induced sputum: By inhalation of hypertonic saline aerosol - used for PCP diagnosis in HIV patients
• Fixed sputum (Saccomano technique): Collected in 50% ethanol + 2% polyethylene glycol, concentrated by blending

• PCP: Foamy alveolar exudate in induced sputum; cysts on GMS stain
• Tuberculosis: AFB stain (Ziehl-Neelsen); but sputum AFB smear is 40-60% sensitive
• Fungal infections: Aspergillus hyphae (acute angle branching), Cryptococcus (encapsulated yeasts), Histoplasma (intracellular yeast in macrophages)
• Asthma: Charcot-Leyden crystals, Curschmann spirals, eosinophils
• Viral infections: Nuclear inclusions (CMV, HSV, measles)
• Actinomycosis: Sulfur granules

10. FNAC of Cystic Lesions of Salivary Gland

Non-neoplastic cysts:

• Mucous retention cyst (mucocele): Thin watery/mucinous fluid, macrophages, occasional ductal cells; no atypical cells
• Lymphoepithelial cyst: Mature squamous cells + lymphocytes; acellular keratin debris; no atypia
• Branchial cleft cyst (parotid): Squamous cells, cholesterol crystals, lymphocytes
• Dermoid cyst: Squamous cells, keratin flakes, hair, sebaceous material

Neoplastic cystic lesions:

• Mucoepidermoid carcinoma can mimic a benign mucocele if low-grade
• Acinic cell carcinoma can be mistaken for normal parotid tissue
• Cystic metastatic SCC in parotid nodes can mimic branchial cleft cyst
• Scant cellularity leads to indeterminate diagnosis

11. Squash Cytology in CNS

1. A 1-2 mm tissue fragment is placed on a clean slide
2. A second slide is gently but firmly pressed and slid to create a thin smear
3. Fixed immediately in 95% ethanol (for Papanicolaou) or air-dried (for Giemsa)
4. Rapid staining: Toluidine blue (2-3 min), rapid H&E, Diff-Quik

• Results in 15-20 minutes
• Preserves cytological detail better than frozen sections
• No freezing artifact (important in brain - high water content causes ice crystal artifact)
• Requires very small tissue (1-2 mm sufficient)
• Excellent for identifying tumor type and guiding extent of resection

• Architecture is lost (only cytological features)
• Fibrous/calcified tumors crush poorly
• Skill-dependent
• Final diagnosis on permanent paraffin sections

12. Milan System for Reporting Salivary Gland Cytopathology (MSRSGC)

• Category III (AUS) is a "gray zone" - should be used sparingly (<10% of cases)
• Category IVB (SUMP) is unique to Milan - for tumors where benign vs. malignant distinction is impossible on cytology alone (e.g., cellular pleomorphic adenoma vs. carcinoma ex-PA; cellular acinic cell carcinoma)
• ROM values guide clinical management
• Encourages use of ancillary tests (IHC, molecular) to reduce indeterminate categories

13. Paris System for Reporting Urinary Cytology (TPS)

• N:C ratio >0.7
• Hyperchromatic nucleus
• Irregular nuclear membrane

• Paris system does NOT attempt to diagnose low-grade carcinoma on cytology (low sensitivity ~20%) - its primary goal is HGUC detection
• LGUN category recognizes cytological features of low-grade neoplasia without claiming diagnostic certainty
• AUC category is analogous to ASC-US in cervical cytology
• Ancillary tests: FISH (UroVysion) improves sensitivity for HGUC; used in AUC/SHGUC categories

14. FNAC of Lymph Node Lesions

Reactive/Inflammatory:

Lymphomas:

Metastatic tumors:

• Flow cytometry (clonality in lymphomas - B-cell restriction)
• IHC panel (CD20, CD3, CD10, BCL2, BCL6, MYC, CD30, ALK)
• Cytogenetics/FISH (t(14;18) follicular; t(8;14) Burkitt's; t(2;5) ALCL)
• Molecular: PCR for IGH/TCR clonality

15. Recent Advances in Cytology

A. Molecular Cytology / Cytogenomics

• Next-Generation Sequencing (NGS) on cytology specimens: FNAC, effusions, and brushings can be used for comprehensive genomic profiling (mutations, fusions, copy number variations). Validated for lung (EGFR, ALK, ROS1, KRAS), thyroid (BRAF, RAS, RET/PTC), and pancreatic (KRAS, TP53) cytology.
• Cell-free DNA / liquid biopsy integration: Cytology-guided procedures paired with ctDNA analysis from plasma.
• FISH on cytological preparations: Routine for bladder (UroVysion), lung (ALK rearrangement), and soft tissue tumors.

B. Digital Cytology and AI

• Whole Slide Imaging (WSI): Digital scanning of cytological preparations for remote reporting (telepathology), archiving, and education.
• Artificial Intelligence / Deep Learning: FDA-approved AI algorithms for cervical cytology screening (Hologic Genius, BD FocalPoint). Studies show AI-assisted screening reduces false negatives and workload. AI tools for thyroid FNAC, effusion cytology, and urine cytology are under validation.
• Computer-Assisted Detection (CAD): Integrates with liquid-based cytology platforms.

C. Reporting Systems Standardization

• Milan System for Salivary Glands (2018)
• Paris System for Urine (2016, updated 2022)
• Bethesda System for Thyroid (2023 edition - 3rd)
• Yokohama System for pancreatobiliary cytology (2022)
• International System for Reporting Serous Fluid Cytopathology (ISRSFC, 2020)
• International Academy of Cytology (IAC) Pancreas System

D. EUS-FNA / EUS-FNB

• Endoscopic ultrasound-guided FNA (EUS-FNA) for pancreas, mediastinum, and subepithelial GI lesions.
• Transition to EUS-FNB (fine needle biopsy) using Franseen, Fork-tip, SharkCore needles - provides core tissue for histology + IHC + molecular testing.
• Rapid On-Site Evaluation (ROSE): Cytopathologist present during EUS to assess adequacy in real time, reducing non-diagnostic rates.

E. Liquid Biopsy in Cytology

• Circulating tumor cells (CTCs): Captured from blood and examined morphologically + molecularly (EpCAM-based capture, CellSearch system).
• ctDNA/cfDNA: Mutation profiling without tissue biopsy.

F. Immunocytochemistry Advances

• Cell block technique improvements allow full IHC panels from FNAC material.
• INSM1 (insulinoma-associated protein 1) as a new neuroendocrine marker superior to synaptophysin in cytology.
• GATA3 for urothelial and breast carcinoma in effusions.
• NKX2.1 (TTF-1) for lung adenocarcinoma confirmation on cytology.

G. Telecytology / Remote Cytology

• Real-time transmission of digital images for expert consultation.
• Critical during COVID-19 pandemic; now adopted as standard practice in many centers.

H. Ancillary Testing on Residual LBC Material

• HPV genotyping, p16/Ki67 dual staining (CINtec PLUS) from residual ThinPrep/SurePath material.
• p16/Ki67 as triage for HPV+ women instead of colposcopy.

I. Novel Specimen Types

• Uterine lavage cytology for endometrial sampling (Tao brush, Pipelle).
• Nipple discharge cytology supplemented by ductal lavage.
• Oral rinse cytology for HPV-associated oropharyngeal cancer screening.

J. PD-L1 and Biomarker Testing on Cytology

• PD-L1 IHC (22C3, 28-8 clones) validated on cytological cell blocks for lung, bladder, gastric cancer.
• Tumor mutational burden (TMB) from FNAC-derived NGS data.
• NTRK fusion testing (FISH/IHC/NGS) on cytology specimens for pan-tumor TRK inhibitor eligibility.

Obesity as a Chronic Systemic Disease

1. Definition and Classification

Definition

BMI-Based Classification (WHO)

Alternative Classification by Body Fat Distribution

• Excess fat predominantly in the abdomen and visceral compartment
• "Apple-shaped" body habitus
• Waist circumference >102 cm (men) or >88 cm (women) - WHO criteria; >90 cm (men) or >80 cm (women) - Asian criteria
• Waist-to-hip ratio (WHR) >0.9 (men) or >0.85 (women)
• Strongly associated with metabolic syndrome, T2DM, cardiovascular disease

• Excess fat in the gluteal, femoral, and subcutaneous compartments
• "Pear-shaped" body habitus
• Less strongly associated with metabolic complications; in some studies shown to be protective
• More common in premenopausal women (estrogen-mediated)

Etiological Classification

• Primary (essential) obesity: Polygenic, multifactorial - the vast majority of cases
• Secondary obesity: Due to identifiable causes:
  • Endocrine: Hypothyroidism, Cushing's syndrome, hypothalamic disorders, hypogonadism, PCOS, growth hormone deficiency, insulinoma
  • Genetic syndromes: Prader-Willi, Bardet-Biedl, Alstrom, Cohen syndromes
  • Medications: Glucocorticoids, antipsychotics (olanzapine, clozapine), antidepressants (tricyclics, mirtazapine), insulin, sulfonylureas, valproate, lithium
  • Monogenic obesity: Leptin deficiency, leptin receptor mutations, MC4R mutations, POMC mutations

Body Fat Measurement Methods

• BMI: Simple, widely used, but does not differentiate fat from muscle mass
• Waist circumference and WHR: Better markers of visceral adiposity
• Dual-energy X-ray absorptiometry (DEXA): Gold standard for body composition
• Bioelectrical impedance analysis (BIA): Portable, estimates fat mass
• CT/MRI: Quantifies visceral vs. subcutaneous fat depots directly
• Skinfold thickness measurements: Anthropometric estimation

2. Epidemiology and Etiological Factors

Epidemiology

• Global prevalence: As of 2022, over 1 billion people worldwide have obesity (WHO). More than 650 million adults, 340 million adolescents, and 39 million children were obese.
• In 2022, 43% of adults worldwide were overweight (BMI ≥25) and 16% were obese.
• Prevalence has tripled since 1975.
• United States: ~42% of adults have obesity; 10% have severe obesity (CDC, 2023).
• India: Overweight/obesity prevalence has risen sharply; NFHS-5 (2019-21) reported ~24% of women and ~23% of men overweight or obese.
• Obesity accounts for approximately 5 million deaths per year globally.
• Economic burden: Annual healthcare costs attributed to obesity in the US exceed $170 billion.
• Childhood obesity is a major concern - obese children are 5x more likely to be obese adults.
• Obesity prevalence is higher in urban, high-income countries but is rising fastest in low- and middle-income countries.

Etiological Factors

A. Genetic Factors

• Twin studies demonstrate that approximately 70% of the tendency to obesity is genetic (Mulholland & Greenfield's Surgery, 7e). Heritability estimates for BMI range from 40-75%.
• Genome-wide association studies (GWAS) have identified over 1,000 BMI-associated genetic loci; over 50 SNPs are confirmed to correlate with human obesity. Individual SNP effect size is small (1-3% each), confirming obesity as a complex polygenic disorder.
• Key obesity-associated genes include: FTO (fat mass and obesity-associated gene - strongest known common variant), MC4R (melanocortin 4 receptor - 5% of human obesity cases), LEP/LEPR (leptin/leptin receptor), PCSK1, BDNF, TMEM18, SH2B1.
• Monogenic obesity (e.g., complete leptin deficiency due to LEP mutation, MC4R loss-of-function) causes severe early-onset obesity.

B. Environmental and Lifestyle Factors ("Obesogenic Environment")

• Caloric surplus: Ultra-processed foods, high-fructose corn syrup, increased portion sizes, energy-dense and nutrient-poor diets
• Physical inactivity: Sedentary occupations, screen time, reduced active transport
• Sleep deprivation: Disrupts ghrelin/leptin balance; increases appetite and food reward
• Stress: Chronic stress elevates cortisol, promoting visceral fat accumulation and emotional eating
• Food environment: Food deserts, food marketing, socioeconomic barriers to healthy diet

C. Epigenetic and Developmental Factors

• Thrifty phenotype hypothesis (Hales & Barker, 1992): Maternal malnutrition leads to fetal programming toward a thrifty metabolism, increasing adult obesity risk (Developmental Origins of Health and Disease - DOHaD hypothesis).
• Maternal obesity and gestational diabetes mellitus increase offspring obesity risk through epigenetic programming.
• Epigenetic modifications (DNA methylation, histone acetylation) alter gene expression without changing DNA sequence.
• Early childhood nutrition, antibiotic exposure, cesarean delivery (altering microbiome colonization) are also implicated.

D. Neuroendocrine Factors

• Dysfunction of the hypothalamic feeding center (HFC), particularly the arcuate nucleus, disrupts energy homeostasis.
• Impaired leptin signaling (leptin resistance) in the hypothalamus is a key mechanism.
• Altered gut hormone signaling (GLP-1, PYY, ghrelin, CCK).

E. Socioeconomic and Cultural Factors

• In high-income countries, obesity is more prevalent in lower socioeconomic groups (inverse relationship with education and income).
• Food advertising, cultural norms around body weight, access to recreational spaces.

F. Iatrogenic and Medical Causes

• Medications (as noted above)
• Smoking cessation (average 4-5 kg weight gain)
• Physical disability limiting activity

3. Pathogenesis

A. Central Regulation of Energy Homeostasis

• Leptin (from adipocytes): Acts on ARCN POMC neurons to reduce food intake and increase energy expenditure; signals adequate fat stores.
• Insulin (from pancreatic β cells): Reduces food intake via hypothalamic pathways.
• PYY 3-36 (from L-cells of gut): Postprandial suppression of appetite.
• GLP-1 (from L-cells of gut): Incretin and satiety hormone; slows gastric emptying.
• CCK (from duodenum/jejunum): Promotes satiety via vagus nerve.
• Oxyntomodulin, neurotensin

• Ghrelin (from stomach): The only known orexigenic gut hormone; rises before meals and falls after.
• NPY/AgRP neurons in ARCN: Stimulate food intake.

B. Genetic and Epigenetic Mechanisms

• Thrifty gene hypothesis: Genes selected for efficient energy storage during evolutionary food scarcity become maladaptive in the modern calorie-abundant environment.
• FTO gene: Intronic SNPs in FTO increase BMI by ~0.4 kg/m² per risk allele. FTO regulates demethylation of m6A RNA, affecting transcription of IRX3 and IRX5, genes involved in adipocyte thermogenesis - risk alleles promote white adipocyte differentiation over beige.
• MC4R mutations: Loss-of-function mutations cause hyperphagia and severe obesity by reducing the anorexigenic effect of alpha-MSH (derived from POMC cleavage).
• Epigenetic programming: Maternal diet-induced histone modifications and DNA methylation patterns alter expression of genes governing appetite, adipogenesis, and insulin sensitivity in offspring. Key epigenetic marks include methylation of the POMC promoter, Leptin gene, and PPAR-γ promoter. These marks are potentially heritable across generations (transgenerational epigenetic inheritance).

C. Adipose Tissue Pathogenesis

• Adipocyte hypertrophy (increase in cell size) is the primary early response to caloric excess; hyperplasia (increase in adipocyte number) occurs later.
• PPAR-γ (peroxisome proliferator-activated receptor gamma) and C/EBP-α are the master transcriptional regulators of adipogenesis.
• As adipocytes enlarge, they exceed the oxygen diffusion distance (~100 μm), causing adipocyte hypoxia, which triggers HIF-1α, ER stress, oxidative stress, and eventually adipocyte apoptosis and necrosis.

1. Nutrient excess → ER stress + oxidative stress in adipocytes
2. Hypertrophy → hypoxia → apoptosis/necrosis
3. Dead adipocytes recruit macrophages (forming "crown-like structures" - CLS)
4. Macrophage polarization toward pro-inflammatory M1 phenotype
5. Release of TNF-α, IL-6, IL-1β, MCP-1 (monocyte chemoattractant protein-1)
6. Inflammation triggers fibrotic remodeling, limiting further adipocyte expansion
7. Lipid, nutrient, and inflammatory mediator overflow into systemic circulation → systemic metabolic disease

D. Hormonal Mechanisms

• Produced by white adipocytes in proportion to fat mass.
• In obesity, circulating leptin is markedly elevated but central resistance develops.
• Peripherally, hyperleptinemia promotes pro-inflammatory responses, endothelial dysfunction, and thrombosis (via elevated plasminogen activator inhibitor-1).

• Anti-inflammatory, insulin-sensitizing adipokine; levels are inversely proportional to fat mass - decreased in obesity.
• Activates AMPK in liver and muscle, promoting fatty acid oxidation and reducing gluconeogenesis.
• Low adiponectin correlates with insulin resistance, T2DM, atherosclerosis, and NASH.

• Excess circulating free fatty acids (FFAs) - particularly from lipolytic visceral adipose tissue - activate serine kinases (IKK-β, JNK) that phosphorylate insulin receptor substrate-1 (IRS-1) at serine residues (instead of tyrosine), impairing downstream PI3K/Akt signaling.
• Intramyocellular and intrahepatic lipid accumulation (lipotoxicity) further impairs insulin signaling.
• Elevated diacylglycerol (DAG) and ceramide species (from FFA metabolism) activate PKC-θ (in muscle) and PKC-ε (in liver), contributing to insulin resistance.

E. Inflammatory Mechanisms (Meta-inflammation)

• Adipose tissue macrophages (ATMs) accumulate progressively with obesity; M1:M2 ratio increases dramatically.
• Key mediators: TNF-α, IL-6, IL-1β, MCP-1, PAI-1 (all increased); adiponectin (decreased).
• Inflammasome activation (NLRP3): Saturated fatty acids and cholesterol crystals activate NLRP3 inflammasome in adipose macrophages and β cells, leading to IL-1β and IL-18 secretion, driving insulin resistance and β cell dysfunction (Robbins & Kumar Basic Pathology).
• T-cell infiltration: CD8+ T cells are early infiltrators in obese adipose tissue, preceding macrophage infiltration; they release IFN-γ and recruit M1 macrophages.
• Crown-like structures (CLS): Histological hallmark of inflamed adipose tissue - macrophage rings around dead adipocytes, visible on H&E as aggregates of macrophages surrounding a large lipid droplet.
• Systemic meta-inflammation drives: insulin resistance, endothelial dysfunction, atherosclerosis, NASH, cancer risk.

F. Molecular Mechanisms

• mTORC1 activation: Nutrient excess activates mTOR complex 1 via PI3K-Akt pathway; mTORC1 promotes lipogenesis, inhibits autophagy, and drives S6K1-mediated serine phosphorylation of IRS-1, impairing insulin signaling.
• AMPK suppression: Caloric excess suppresses AMPK (AMP-activated protein kinase), the cellular energy sensor; reduced AMPK promotes lipogenesis and inhibits fatty acid oxidation.
• ER stress (Unfolded Protein Response - UPR): Nutrient overload overwhelms ER folding capacity; UPR activates IRE1α-JNK and PERK-eIF2α pathways that inhibit insulin signaling.
• Oxidative stress: Excess substrate increases ROS production from mitochondria; ROS activates NF-κB, promoting pro-inflammatory gene expression.
• NF-κB pathway: Activated by FFAs (via TLR4), cytokines, and ROS; drives expression of TNF-α, IL-6, IL-1β, ICAM-1, promoting insulin resistance and endothelial dysfunction.
• Ceramide signaling: Saturated FFAs promote de novo ceramide synthesis; ceramides activate PP2A (protein phosphatase 2A), which dephosphorylates and inactivates Akt, blocking insulin signaling.

4. Pathological Changes in Adipose Tissue and Organ Pathology

A. Adipose Tissue Pathology

• Adipocyte hypertrophy: Enlarged unilocular lipid droplets; cells may exceed 150 μm diameter (normal ~80-100 μm).
• Crown-like structures (CLS): Macrophage aggregates encircling dead or dying adipocytes - the histological hallmark of adipose tissue inflammation. Correlates with insulin resistance and metabolic disease severity.
• Macrophage infiltration: ATMs constitute 10% of stromal-vascular fraction in lean adipose tissue but up to 40-50% in obese adipose tissue.
• Fibrosis: Collagen deposition around adipocytes and in the interstitium; limits adipocyte expansion, impairs metabolic function, and is associated with more severe metabolic complications.
• Hypoxia: HIF-1α expression, reduced vascular density relative to tissue volume.
• Lymphocyte infiltration: CD8+ T cells, CD4+ T cells (Th1 predominant), mast cells.
• Stromal-vascular fraction changes: Increased M1 macrophages, decreased M2 macrophages; Treg depletion.

• Visceral adipose tissue: More lipolytic, more inflammatory, more macrophage-infiltrated, directly drains into portal circulation (delivering FFAs and cytokines to the liver).
• Subcutaneous adipose tissue: More insulin-sensitive, produces more adiponectin, acts as a metabolic "buffer."
• Ectopic fat deposition (hepatic steatosis, intramyocellular fat, epicardial fat, perivascular fat, pancreatic fat) occurs when adipose buffering capacity is overwhelmed.

B. Liver Pathology (MASLD/NASH)

• Hepatic steatosis (simple fatty liver): Macrovesicular steatosis >5% of hepatocytes; reversible.
• Metabolic-Associated Steatohepatitis (MASH/NASH): Steatosis + lobular inflammation (mixed inflammatory infiltrate) + hepatocyte ballooning + variable fibrosis. NAFLD Activity Score (NAS) is used for grading.
• Fibrosis progression: Perisinusoidal/pericellular fibrosis (zone 3) → bridging fibrosis → cirrhosis → hepatocellular carcinoma.
• Pathogenesis: Insulin resistance → hepatic free fatty acid overflow → lipid peroxidation → oxidative stress → inflammatory cytokines → stellate cell activation → fibrosis ("two-hit" and "multiple parallel hits" models).
• Obesity ≥40 kg/m² is associated with ~10x increased risk of liver-related death.

C. Cardiovascular Pathology

• Atherosclerosis: Obesity promotes atherogenesis via dyslipidemia (elevated VLDL/LDL, low HDL), hypertension, endothelial dysfunction, systemic inflammation, and oxidative stress.
• Cardiac hypertrophy: Increased cardiac workload due to increased blood volume and peripheral resistance → left ventricular hypertrophy (LVH) → diastolic dysfunction → heart failure with preserved ejection fraction (HFpEF).
• Epicardial fat: A metabolically active visceral fat depot surrounding the heart; produces pro-inflammatory and pro-atherogenic adipokines (leptin, resistin, visfatin); directly infiltrates the myocardium in severe obesity.
• Cardiomyopathy of obesity: Direct lipotoxic cardiomyopathy from lipid accumulation in cardiomyocytes (myocardial steatosis).
• Pulmonary hypertension: From hypoxemia (obesity hypoventilation) and endothelial dysfunction.

D. Pancreatic Pathology

• Pancreatic steatosis ("fatty pancreas"): Lipid infiltration of pancreatic parenchyma; impairs exocrine and endocrine function.
• Islet amyloid: In T2DM associated with obesity; amyloid polypeptide (IAPP/amylin) accumulates in islets, contributing to β cell loss.
• β cell exhaustion: Chronic hyperinsulinemia from insulin resistance → β cell ER stress and apoptosis → frank T2DM.
• Increased risk of pancreatic adenocarcinoma (obesity is a recognized risk factor).

E. Renal Pathology

• Obesity-related glomerulopathy (ORG): Focal segmental glomerulosclerosis (FSGS) variant - characterized by glomerulomegaly and focal segmental sclerosis without significant podocyte effacement (unlike idiopathic FSGS). Proteinuria (usually subnephrotic), progressive.
• Hyperfiltration: Obesity causes glomerular hyperfiltration via renin-angiotensin-aldosterone system (RAAS) activation, hyperinsulinemia, and increased renal tubular sodium reabsorption.
• Increased risk of nephrolithiasis (uric acid stones).
• Obesity is a risk factor for CKD progression.

F. Other Organ Pathology

• Skeletal system: Increased load on weight-bearing joints → osteoarthritis (knee, hip); altered biomechanics.
• Endometrium: Excess peripheral estrogen production (aromatization in adipose tissue) → endometrial hyperplasia and endometrial carcinoma.
• Breast: Increased estrogen → increased risk of postmenopausal breast cancer.
• Respiratory: Obstructive sleep apnea (OSA) from pharyngeal fat; obesity hypoventilation syndrome (OHS); reduced chest wall compliance; increased asthma risk.
• Gallbladder: Cholesterol supersaturation of bile → cholelithiasis (gallstones) in 3x increased risk.
• Skin: Acanthosis nigricans (marker of insulin resistance), intertrigo (in skin folds), striae, lymphedema.
• CNS: Idiopathic intracranial hypertension (pseudotumor cerebri); increased dementia risk; depression.

5. Obesity-Associated Metabolic Syndrome and Systemic Complications

Metabolic Syndrome

Systemic Complications of Obesity

6. Laboratory Evaluation and Biomarkers

Routine Evaluation

• BMI, waist circumference, WHR, waist-to-height ratio (>0.5 is a risk indicator)

Specialized Biomarkers

• Leptin: Elevated in obesity (often 5-10x normal); correlates with fat mass; leptin resistance present despite high levels.
• Adiponectin: Decreased in obesity; low levels predict T2DM and CVD; target value >10 μg/mL is considered protective.
• Resistin: Elevated in obesity; promotes insulin resistance; pro-inflammatory.
• Visfatin/NAMPT: Elevated in visceral obesity; promotes inflammatory signaling.
• Chemerin: Elevated in obesity; promotes adipogenesis and inflammation.
• Omentin: Decreased in obesity; anti-inflammatory; insulin sensitizer.
• FGF21 (fibroblast growth factor 21): Elevated in MASLD and metabolic syndrome; potential therapeutic target.

• hsCRP: >3 mg/L indicates high cardiovascular risk; elevated in obesity.
• IL-6: Elevated; predicts T2DM and CVD risk.
• TNF-α: Elevated in adipose tissue; contributes to insulin resistance.
• Fetuin-A: Elevated in obesity/MASLD; endogenous inhibitor of insulin signaling; predicts T2DM.
• Fibrinogen, PAI-1: Elevated; contribute to prothrombotic state.

• FIB-4 score [age × AST / (platelets × √ALT)]: Non-invasive fibrosis assessment in MASLD.
• NAFLD Fibrosis Score (NFS): Estimates fibrosis stage from clinical parameters.
• Enhanced Liver Fibrosis (ELF) panel: Serum markers of hepatic fibrosis (PIIINP, hyaluronic acid, TIMP-1).
• Liver stiffness (FibroScan/transient elastography): Non-invasive assessment of fibrosis stage.

• Apolipoprotein B (ApoB): Better marker of atherogenic particle burden than LDL-C.
• Non-HDL cholesterol: Includes VLDL and IDL; superior to LDL in hypertriglyceridemia.
• Lipoprotein(a) [Lp(a)]: Independently elevated cardiovascular risk.
• BNP/NT-proBNP: Elevated in obesity-related cardiac dysfunction.

• OGTT (oral glucose tolerance test): For T2DM/prediabetes diagnosis.
• Fasting C-peptide: Assesses residual β cell function.
• Sex hormone profile (testosterone, LH, FSH, SHBG) for PCOS/hypogonadism.

7. Recent Advances

A. Adipose Tissue Immunobiology and Meta-inflammation

• Adipose tissue immune cell landscape: Lean adipose tissue contains anti-inflammatory immune cells - M2 macrophages, regulatory T cells (Tregs), ILC2s (type 2 innate lymphoid cells), and eosinophils - that maintain insulin sensitivity via IL-10, IL-4/IL-13 signaling. Obesity causes a shift toward M1 macrophages, CD8+ T cells, CD4+ Th1 cells, NK cells, and mast cells.
• Crown-Like Structures (CLS): Each CLS represents macrophages attempting to scavenge a dying adipocyte. The number of CLS per unit area of adipose tissue correlates with insulin resistance, hepatic steatosis, and cardiovascular risk better than BMI alone.
• Adipose tissue B cells: Emerging data show that obese adipose tissue accumulates B cells, which produce IgG antibodies that activate macrophages via Fcγ receptor signaling, amplifying inflammation.
• Adipose tissue resident macrophage subtypes: Single-cell RNA sequencing has identified distinct macrophage populations in adipose tissue: lipid-associated macrophages (LAMs) that accumulate in obese adipose tissue and express Trem2, ABCA1, and CD9; these may have both protective (lipid handling) and pathological (inflammatory) roles.
• Meta-inflammation vs. classical inflammation: Meta-inflammation is characterized by: lower intensity, chronic persistence, systemic distribution, metabolic rather than microbial triggers (sterile inflammation), and activation of pattern recognition receptors (TLRs - particularly TLR4 - by saturated fatty acids acting as DAMPs).
• NLRP3 inflammasome: A key mechanism linking nutrient excess to IL-1β production; NLRP3 inhibitors (MCC950 and others) are under clinical investigation.

B. Gut Microbiome and Obesity

• Dysbiosis in obesity: Obese individuals show decreased microbial diversity, reduced abundance of short-chain fatty acid (SCFA)-producing bacteria (Firmicutes/Bacteroidetes ratio changes, increased Firmicutes), and enrichment of energy-harvesting bacteria.
• Mechanisms linking microbiome to obesity:
  • SCFAs (butyrate, propionate, acetate) produced by gut bacteria act as signaling molecules via GPR41/GPR43 receptors on enteroendocrine cells, stimulating PYY and GLP-1 secretion - reducing appetite and improving insulin sensitivity.
  • Leaky gut / increased intestinal permeability: Obesity-associated dysbiosis reduces tight junction proteins (occludin, ZO-1), allowing bacterial lipopolysaccharide (LPS) to translocate into portal circulation, triggering metabolic endotoxemia - TLR4-mediated activation of NF-κB and pro-inflammatory cascade.
  • Microbiome modulates bile acid metabolism, influencing FXR and TGR5 receptor signaling (important for energy expenditure and glucose homeostasis).
  • Trimethylamine N-oxide (TMAO) production from dietary choline/carnitine by gut bacteria promotes atherosclerosis.
• Fecal microbiota transplantation (FMT): Transfer from lean to obese individuals has shown modest improvements in insulin sensitivity in clinical trials; not yet established as a standard treatment.
• Probiotics and prebiotics: Clinical trials show modest but inconsistent benefits on BMI and metabolic parameters.
• Microbiome as a biomarker: Metagenomics can identify dysbiotic patterns predictive of metabolic syndrome risk.

C. Epigenetics and Metabolomics in Obesity

• DNA methylation: Obesity is associated with differential methylation at thousands of CpG sites. Key loci include POMC, LEP, ADIPOQ, and PPARG promoters. GWAS + methylation studies (mQTL) identify CpG sites that mediate genetic risk variants' effects on obesity.
• Histone modifications: H3K27 acetylation and H3K4 methylation at enhancers of adipogenic genes (C/EBP-α, PPAR-γ) are altered in obesity. Histone deacetylase (HDAC) inhibitors are being studied as therapeutic agents.
• Non-coding RNAs: MicroRNAs (miR-33, miR-122, miR-155, miR-221) regulate adipogenesis, lipid metabolism, and inflammation. Circulating miRNAs are being explored as non-invasive biomarkers. Long non-coding RNAs (lncRNAs - e.g., HOTAIR, lnc-HC) modulate chromatin remodeling in adipose tissue.
• Transgenerational epigenetic inheritance: Paternal obesity has been shown to alter sperm miRNA profiles and DNA methylation patterns, transmitting metabolic risk to offspring.

• Untargeted metabolomics identifies altered plasma metabolite profiles in obesity:
  • Branched-chain amino acids (BCAAs - leucine, isoleucine, valine): Elevated in obesity and T2DM; activate mTOR/S6K1 and contribute to insulin resistance; predictors of T2DM risk.
  • Aromatic amino acids (tyrosine, phenylalanine): Elevated; linked to insulin resistance.
  • Acylcarnitines: Elevated; reflect incomplete β-oxidation ("metabolic bottleneck"); associated with insulin resistance.
  • Sphingolipids (ceramides): Elevated; mediators of lipotoxicity and insulin resistance.
  • Lysophosphatidylcholines: Altered; linked to metabolic dysfunction.
  • Trimethylamine N-oxide (TMAO): Elevated; cardiovascular risk marker.
• Metabolomics signatures can distinguish simple obesity from metabolic syndrome and identify individuals at highest cardiometabolic risk.

D. Brown and Beige Adipose Tissue Biology

• Multilocular adipocytes rich in mitochondria; express UCP-1 (uncoupling protein-1) - also called thermogenin - which uncouples the mitochondrial proton gradient from ATP synthesis, dissipating energy as heat.
• Activated by cold exposure and sympathetic nervous system (β3-adrenergic receptors).
• In adults, BAT is present in cervical, supraclavicular, mediastinal, paraspinous, and perirenal depots; detectable by ¹⁸F-FDG PET/CT.
• BAT mass and activity are inversely correlated with BMI and visceral fat.
• BAT-derived secretory factors (batokines): FGF21, neuregulin 4, IL-6, meteorin-like, 12,13-diHOME - have systemic beneficial metabolic effects.
• BAT activity can be stimulated by: cold exposure, β3-agonists (mirabegron - in trials), FGF21 analogs, thyroid hormone analogs.

• Intermediate phenotype: UCP-1+ cells that emerge within white adipose tissue depots in response to stimuli ("browning" of white fat).
• Develop from distinct precursors (Sca1+/PDGFR-α+ progenitors in subcutaneous WAT) - different from classical brown adipocytes (myogenic precursors).
• Induced by: cold, β3-adrenergic stimulation, exercise (via irisin/FNDC5 from muscle), thyroid hormones, PPAR-γ agonists (thiazolidinediones), FGF21.
• Irisin (cleaved from FNDC5, secreted by exercising muscle): Promotes browning of subcutaneous WAT; improves insulin sensitivity; reduces hepatic steatosis in animal models. Circulating irisin levels are reduced in obese/T2DM individuals.
• Pharmacological browning of WAT is an active therapeutic target - could increase daily energy expenditure by several hundred kcal.
• FTO gene risk variants are now known to work partly by impairing IRX3/IRX5-mediated browning of adipocytes.

E. Novel Adipokines and Inflammatory Biomarkers

• Asprosin: Fasting-induced glucogenic hormone secreted by subcutaneous white adipose tissue; activates liver glucose release and hypothalamic orexigenic neurons via GPR107. Elevated in obesity and T2DM; anti-asprosin antibodies show anti-obesity effects in mice.
• Nesfatin-1: Satiety signal produced by adipocytes and hypothalamic neurons; decreased in obesity; acts on oxytocin neurons.
• Apelin: Dual role - improves insulin sensitivity at physiological levels but promotes obesity at high levels; mediates post-exercise metabolic benefits.
• Meteorin-like (Metrnl): Secreted by BAT/beige adipocytes and adipose macrophages; promotes adipose tissue beiging; anti-inflammatory.
• Lipocalin-2 (NGAL): Elevated in obesity; pro-inflammatory adipokine; promotes insulin resistance and NF-κB activation.
• RBP4 (retinol-binding protein 4): Elevated in visceral obesity; impairs insulin signaling in muscle and liver.
• CXCL5: Adipokine that impairs insulin signaling via JNK activation; elevated in human obesity.
• Progranulin: Elevated in obesity; activates TNF receptor signaling; contributes to insulin resistance.
• Fibroblast growth factor 21 (FGF21): Liver-derived (and adipose) endocrine factor; promotes fatty acid oxidation, BAT thermogenesis, beige adipogenesis; decreases in response to carbohydrate restriction; paradoxically elevated in MASLD (likely representing resistance state). FGF21 analogs (efruxifermin, pegozafermin) are in Phase 3 trials for MASLD.

• GDF15 (growth differentiation factor 15): Anti-obesity hormone secreted in response to cellular stress (metformin, exercise, disease); signals via GFRAL receptor in hindbrain to reduce appetite; being explored as therapeutic target.
• CXCL10/IP-10: Elevated in adipose tissue of obese individuals; attracts Th1 cells and NK cells.
• Galectin-3: Elevated in obesity-related inflammation; promotes M2→M1 macrophage polarization.

F. GLP-1/GIP-Based Therapies and Their Pathological Basis

• An incretin hormone secreted by L-cells of the distal ileum and colon in response to nutrient ingestion.
• Actions: Stimulates insulin secretion (glucose-dependent), inhibits glucagon, slows gastric emptying, acts on hypothalamic POMC neurons to reduce appetite via GLP-1R in ARC and NTS (nucleus tractus solitarius).
• Rapidly degraded by DPP-4 (dipeptidyl peptidase-4) with a half-life of ~2 minutes.
• In obesity, postprandial GLP-1 secretion is impaired, contributing to hyperphagia.

• DPP-4 resistant analogs with extended half-lives.
• Liraglutide (Saxenda): Daily SC injection; 3 mg/day for obesity; ~5-8% weight loss vs. placebo.
• Semaglutide (Wegovy): Weekly SC injection; 2.4 mg/week; ~15% weight loss (STEP trials). Oral semaglutide (Rybelsus) for T2DM. STEP-4 trial confirmed weight regain after discontinuation.
• Mechanism for weight loss: Appetite suppression via hypothalamic GLP-1R (reduced NPY/AgRP; enhanced POMC); delayed gastric emptying reducing meal size; possible direct effects on reward pathways in the nucleus accumbens reducing food craving.
• Cardiovascular benefits: Semaglutide reduced MACE by 26% in SELECT trial (2023) in non-diabetic obese patients - the first anti-obesity drug with proven CV mortality benefit.

• Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 receptor agonist; weekly SC injection; achieves ~20-22% weight loss (SURMOUNT-1 trial) - surpassing GLP-1 monotherapy; FDA approved for obesity in 2023.
• GIP receptor in hypothalamus and adipose tissue likely contributes to additional efficacy.
• Pathological basis: GIP promotes lipid uptake into adipose tissue under normal conditions (lipid buffering); GIP receptor agonism at hypothalamic level may enhance GLP-1-mediated appetite suppression synergistically.

• Retatrutide (LY3437943): Triple agonist; achieved ~24% weight loss at 48 weeks in Phase 2 trial (NEJM, 2023). Glucagon receptor agonism increases energy expenditure via BAT thermogenesis and hepatic lipid oxidation.
• CagriSema (cagrilintide + semaglutide): Amylin analogue + GLP-1 RA combination; Phase 3 trials ongoing.

• Cagrilintide: Long-acting amylin analogue; promotes satiety via area postrema and NTS; additive weight loss when combined with semaglutide.

• Multiple complementary central and peripheral mechanisms of appetite suppression
• Hormonal mimicry of the natural post-prandial satiety response
• Bariatric surgery outcomes partly mediated by increased endogenous GLP-1 and PYY secretion - validating the GLP-1 pathway as critical to weight regulation.

G. Precision Medicine and AI-Based Risk Prediction

• Phenotypic subtyping: Not all obese individuals have the same metabolic risk. "Metabolically healthy obesity" (MHO) describes obese individuals without metabolic syndrome - though long-term data suggest this is often a transient state.
• Genetic risk scores (PRS - polygenic risk scores): Combining hundreds of BMI-associated SNPs into a PRS can identify individuals at highest genetic risk for obesity and its complications, enabling pre-symptomatic intervention.
• Pharmacogenomics: Genetic variants predict differential response to anti-obesity medications - e.g., MC4R variants affect response to GLP-1 RAs; FTO variants affect response to lifestyle interventions.
• Precision nutrition: Continuous glucose monitoring (CGM)-guided dietary interventions; personalized glycemic responses to foods (Weizmann Institute studies by Segal & Elinav showed postprandial glycemic response varies dramatically between individuals for the same food, driven by microbiome, genetics, and lifestyle).
• Multi-omics integration: Combining genomics, transcriptomics, proteomics, metabolomics, and microbiomics to build comprehensive individual risk profiles ("systems medicine" of obesity).

• Machine learning algorithms for predicting obesity complications (T2DM, CVD) from electronic health record data.
• Deep learning on imaging: AI quantification of visceral vs. subcutaneous fat from routine CT scans (automated body composition analysis); radiomics-based liver fat quantification without liver biopsy.
• AI-powered dietary assessment: Image recognition of food intake for accurate dietary logging (vs. unreliable self-reporting).
• Natural language processing (NLP): Mining EHR data to identify undiagnosed obesity and associated comorbidities.
• Wearables + AI: Continuous physiological monitoring (heart rate variability, sleep, physical activity, CGM data) integrated with AI to generate personalized lifestyle recommendations.
• Drug discovery: AI-assisted identification of novel obesity drug targets by integrating GWAS data, single-cell transcriptomics, and protein structure prediction (AlphaFold-assisted target identification).

H. Emerging Molecular Targets

Summary

Key references: Mulholland & Greenfield's Surgery: Scientific Principles and Practice, 7e (Chapter: Pathogenesis of Obesity and Metabolic Disease); Robbins & Kumar Basic Pathology (Diabetes and Obesity); Harrison's Principles of Internal Medicine, 22e (2025); Sabiston Textbook of Surgery (GLP-1 RAs and Bariatric Surgery); Guyton & Hall Medical Physiology (Insulin Resistance and Metabolic Syndrome).